摘要
目的 通过研究左旋门冬酰胺酶 (L -asp)的药代动力学特点 ,探讨其治疗小儿急性白血病的合理用药时间。方法 检测 1 5例应用常规剂量L -asp [1 0 0 0 0U (m2 ·次 ) ]的急性淋巴细胞白血病患儿 ( 340份外周血样本 )治疗前、治疗中及治疗后多个时间点下患儿血浆L -asp活性 ,动态观察用药过程中血浆L -asp活性及停药后L -asp维持有效作用活性的持续时间。结果 用药过程中 ,血L -asp活性峰值逐渐增高的趋势 ,到第 8次用药开始达到高峰。用药疗程后 ,血L -asp活性持续 7天维持 1 0 0U L以上 ,随后逐渐下降至用药前水平。结论 研究结果表明 ,目前L -asp治疗小儿急性淋巴细胞白血病的用药方案 [1 0 0 0 0U (m2 ·次 ) ,隔天一次 ,用 8～ 1 0次 ]有其药代动力学依据 ,但仍可作出进一步改善。
Objective To investigate the pharmacokinetics of Escherichia coli asparaginase(L-asp) in the treatment of childhood acute lymphoblastic leukemia(All),and then to determine whether the current way using L-asp should be improved. Method A group of 15 children with acute lymphoblastic leukemia were given L-asp 10000 U/(m 2 per dose) intravenously every other day for 10 doses during multiagent induction,reinduction or intensification therapy. Totally 340 peripheral blood samples were collected at various times during therapy for measurement of L-asp activity (spectrophotometric assay) in plasma. Results During the therapies,L-asp activity was increased gradually and reached to stable status after the eighth dose administration. After finishing the last dose of L-asp,the activity above 100 U/L in the plasma could last for seven days. Conclusion Therefore,in the treatment of childhood ALL,the current use of L-asp,10000U/(m 2 per dose)intravenous the other day for 8 to 10 times,reflects its pharmacokinetic features in some degree,but can be improved further.
出处
《中国小儿血液》
2004年第4期145-149,共5页
China Child Blood
